Verteporfin

Chemical formula: C₁₆₄H₁₆₈N₁₆O₃₂  Molecular mass: 718.794 g/mol  PubChem compound: 5362420

Therapeutic indications

Verteporfin is indicated for:

Subfoveal choroidal neovascularisation (CNV)

Population group: only adults (18 years old or older)

Verteporfin is indicated for the treatment of:

  • adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or
  • adults with subfoveal choroidal neovascularisation secondary to pathological myopia.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Verteporfin is contraindicated in the following cases:

Porphyria

Porphyria

Severe hepatic impairment

Hepatic failure stage IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: VISUDYNE Powder for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈